These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 17425432

  • 1. Evaluation of human immunodeficiency virus type 1-infected Chinese patients treated with highly active antiretroviral therapy for two years.
    Zhou HY, Zheng YH, Zhang CY, Chen J, He Y, Ding PP, Li H.
    Viral Immunol; 2007; 20(1):180-7. PubMed ID: 17425432
    [Abstract] [Full Text] [Related]

  • 2. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H, Zheng YH, Shen Z, Liu M, Liu C, He Y, Chen J, Ou QY, Huang ZL.
    Zhonghua Yi Xue Za Zhi; 2007 Nov 13; 87(42):2973-6. PubMed ID: 18261327
    [Abstract] [Full Text] [Related]

  • 3. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study.
    French M, Amin J, Roth N, Carr A, Law M, Emery S, Drummond F, Cooper D, OzCombo 2 investigators.
    HIV Clin Trials; 2002 Nov 13; 3(3):177-85. PubMed ID: 12032876
    [Abstract] [Full Text] [Related]

  • 4. Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study.
    Reliquet V, Allavena C, François-Brunet C, Perré P, Bellein V, Garré M, May T, Souala F, Besnier JM, Raffi F.
    HIV Med; 2006 Oct 13; 7(7):431-6. PubMed ID: 16925728
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
    Ribera E, Rodríguez-Pardo D, Rubio M, Soler A, Pedrol E, Blanco JL, González A, Crespo M, Falcó V, Ocaña I, Deig E, Miró JM, Pahissa A.
    Antivir Ther; 2005 Oct 13; 10(5):605-14. PubMed ID: 16152754
    [Abstract] [Full Text] [Related]

  • 6. [Evaluation of antiretroviral therapy in HIV-infected adults in the Department of Haematology, University Hospital of Brazzavllle, Congo].
    Dokekias AE, Galiba FO, Bokilo AD, Ntsimba P, Nsitou MB, Malanda F, Basseila GB.
    Bull Soc Pathol Exot; 2008 Apr 13; 101(2):109-12. PubMed ID: 18543703
    [Abstract] [Full Text] [Related]

  • 7. [Therapeutic effect and safety evaluation on 6-year highly active antiretroviral therapy for Chinese HIV-1 infected patients].
    Zhou H, Zheng Y, He Y, Gong G, Chen Z, Liu M, Yin W, Liu C.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Aug 13; 34(8):731-7. PubMed ID: 19734579
    [Abstract] [Full Text] [Related]

  • 8. [Safety study of 52-week highly active antiretroviral therapy in 198 HIV/AIDS Chinese patients].
    Li WJ, Dai Y, Han Y, Qiu ZF, Xie J, Zuo LY, Li YL, Li TS.
    Zhonghua Yi Xue Za Zhi; 2011 May 24; 91(19):1318-22. PubMed ID: 21756757
    [Abstract] [Full Text] [Related]

  • 9. Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study.
    Anekthananon T, Ratanasuwan W, Techasathit W, Sonjai A, Suwanagool S.
    J Med Assoc Thai; 2004 Jul 24; 87(7):760-7. PubMed ID: 15521230
    [Abstract] [Full Text] [Related]

  • 10. A one-year clinical trial using didanosine, stavudine and nevirapine for highly active antiretroviral therapy.
    Zhou HY, Zheng YH, Zhang CY, Ding PP, Zou W.
    Chin Med J (Engl); 2005 Apr 05; 118(7):609-11. PubMed ID: 15820096
    [No Abstract] [Full Text] [Related]

  • 11. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
    Elion R, Kaul S, Knupp C, Adler M, Cross AP, Dunkle LM, Kelleher T.
    Clin Ther; 1999 Nov 05; 21(11):1853-63. PubMed ID: 10890257
    [Abstract] [Full Text] [Related]

  • 12. Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal.
    Laurent C, Tchatchueng Mbougua JB, Ngom Guèye NF, Etard JF, Diouf A, Landman R, Molinari N, Girard PM, Sow PS, Ndoye I, Delaporte E, ANRS 1215/1290 Study Group.
    Trop Med Int Health; 2011 Feb 05; 16(2):217-22. PubMed ID: 21087377
    [Abstract] [Full Text] [Related]

  • 13. Combination therapy with stavudine (d4T) plus didanosine (ddI) in children with human immunodeficiency virus infection. The Pediatric AIDS Clinical Trials Group 327 Team.
    Kline MW, Van Dyke RB, Lindsey JC, Gwynne M, Culnane M, Diaz C, Yogev R, McKinney RE, Abrams EJ, Mofenson LM.
    Pediatrics; 1999 May 05; 103(5):e62. PubMed ID: 10224206
    [Abstract] [Full Text] [Related]

  • 14. Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study.
    Liu ZY, Guo FP, Han Y, Qiu ZF, Zuo LY, Li YL, Li TS.
    Chin Med J (Engl); 2009 Oct 20; 122(20):2497-502. PubMed ID: 20079166
    [Abstract] [Full Text] [Related]

  • 15. Poor efficacy and tolerability of stavudine, didanosine, and efavirenz-based regimen in treatment-naive patients in Senegal.
    Canestri A, Sow PS, Vray M, Ngom F, M'boup S, Kane CT, Delaporte E, Gueye M, Peytavin G, Girard PM, Landman R, ANRS 12-06/IMEA 012 Trial Study Group.
    MedGenMed; 2007 Oct 09; 9(4):7. PubMed ID: 18311357
    [Abstract] [Full Text] [Related]

  • 16. Stavudine plus didanosine and nevirapine in antiretroviral-naive HIV-infected adults: preliminary safety and efficacy results. VIRGO Study Team.
    Raffi F, Reliquet V, Francois C, Garre M, Hascoet C, Allavena C, Arvieux C, Breux JP, Perre P, Rozenbaum W, Auger S.
    Antivir Ther; 1998 Oct 09; 3 Suppl 4():57-60. PubMed ID: 10723512
    [Abstract] [Full Text] [Related]

  • 17. A phase II randomized study of the virologic and immunologic effect of zidovudine + stavudine versus stavudine alone and zidovudine + lamivudine in patients with >300 CD4 cells who were antiretroviral naive (ACTG 298).
    Pollard RB, Tierney C, Havlir D, Tebas P, Fox L, Smeaton L, Richman D, Friedland GH.
    AIDS Res Hum Retroviruses; 2002 Jul 01; 18(10):699-704. PubMed ID: 12167276
    [Abstract] [Full Text] [Related]

  • 18. Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: a randomized controlled trial.
    Foudraine NA, Jurriaans S, Weverling GJ, Burger DM, Hoetelmans RM, Roos MT, Maas J, Miedema F, Reiss P, Portegies P, de Wolf F, Lange JM.
    Antivir Ther; 2001 Mar 01; 6(1):55-62. PubMed ID: 11417762
    [Abstract] [Full Text] [Related]

  • 19. Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).
    Lowe SH, Wensing AM, Hassink EA, ten Kate RW, Richter C, Schreij G, Koopmans PP, Juttmann JR, van der Tweel I, Lange JM, Borleffs JC.
    HIV Clin Trials; 2005 Mar 01; 6(5):235-45. PubMed ID: 16306030
    [Abstract] [Full Text] [Related]

  • 20. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial.
    Laurent C, Kouanfack C, Koulla-Shiro S, Nkoué N, Bourgeois A, Calmy A, Lactuock B, Nzeusseu V, Mougnutou R, Peytavin G, Liégeois F, Nerrienet E, Tardy M, Peeters M, Andrieux-Meyer I, Zekeng L, Kazatchkine M, Mpoudi-Ngolé E, Delaporte E.
    Lancet; 2005 Mar 01; 364(9428):29-34. PubMed ID: 15234853
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.